Drug Profile
Topiramate extended release - Upsher-Smith
Alternative Names: Qudexy XR; USL-255Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Upsher-Smith
- Developer SK Chemicals; Upsher-Smith
- Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
- Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Lennox-Gastaut syndrome; Migraine; Partial epilepsies; Tonic-clonic epilepsy
Most Recent Events
- 28 Dec 2022 No development reported - Phase-I for Migraine (Prevention, In volunteers) in South Korea (PO)
- 06 Oct 2020 SK Chemicals completes Phase-I clinical trials in Migraine (In volunteers, Prevention) in South Korea (PO) (NCT04401137)
- 01 Jul 2020 Phase-I clinical trials in Migraine (In volunteers, Prevention) in South Korea (PO) (NCT04401137)